* Anbal-cel targeting DLBCL completes phase 2 trial * Anticipation growing over Korea's first CAR...
* 84% ORR (32 of 38 patients) and 71% CR (27 of 38 patients) documented after 2 million cells/kg ...
- 82% ORR (9 of 11 patients) and 82% (9 of 11 patients) CR rate documented after anbal-cel treatm...
DAEJEON, South Korea, Dec. 23, 2021 Curocell, currently on PhaseⅠCAR-T Therapy clinical trial withC...
DAEJEON, South Korea, Feb. 22, 2021 /PRNewswire/ -- Curocell, Inc., a clinical-stage biotech develo...